Afatinib, an irreversible ErbB-family inhibitor, is recommended as a first-line therapy for eligible patients with metastatic NSCLC harboring uncommon EGFR mutations, such as S768I, L861Q, and/or G719X (25, 41). This evidence concerns the gene EGFR and non-small cell lung carcinoma.